Contact information
Research groups
Professor Sir Andrew Pollard FMedSci FRS
BSc MBBS PhD (Lond), DIC, MRCP (UK), FHEA, FRCPCH, MA, FMedSci, FRS
Ashall Professor of Infection & Immunity
Director of the Oxford Vaccine Group
Sir Andrew is Director of the Oxford Vaccine Group in the Department of Paediatrics at the University of Oxford and a consultant paediatrician at Oxford Children’s Hospital and Fellow of St Cross College. He received a knighthood in the Queen’s Birthday Honours in 2021 for services to Public Health, especially in the pandemic, and received the Order of Medical Merit (Grande Oficial) from the Federal Republic of Brazil in 2022 and is Commander of the Order of Rio Branco. He is host of "the Pandemic People" on the Oxford Colloquy Podcast
He obtained his medical degree at St Bartholomew’s Hospital Medical School, University of London in 1989 and trained in Paediatrics at Birmingham Children’s Hospital, UK, specialising in Paediatric Infectious Diseases at St Mary’s Hospital, London, UK and at British Columbia Children’s Hospital, Vancouver, Canada. He obtained his PhD at St Mary’s Hospital, London, UK in 1999 studying immunity to Neisseria meningitidis in children and proceeded to work on anti-bacterial innate immune responses in children in Canada before returning to his current position at the University of Oxford in 2001. The core of his research has been on investigation of immunity against the polysaccharide encapsulated bacteria that cause serious infections in children and their prevention through vaccination. His research includes novel observations on the B cell response in early childhood, the design, development and clinical evaluation of vaccines in UK, Asia, Africa and Latin America, including those for COVID-19, typhoid, meningococcus, Haemophilus influenzae type b, pneumococcus, plague, Q fever, pertussis, influenza, rabies, coronavirus and Ebola, and leads studies using a human challenge model of paratyphoid and typhoid. His seminal work on typhoid supported the WHO prequalification of a new typhoid conjugate vaccine and WHO recommendations for its use in countries with a high burden of disease. He was the chief investigator for the clinical trials of the Oxford-AstraZeneca COVID-19 vaccine, which led to authorisation of the vaccine for use in more than 180 countries with over 3 billion doses distributed. The COVID19 vaccine team received the Copley Medal from the Royal Society in 2022. He has supervised 50 PhD students and his publications include over 800 manuscripts and books on various topics in paediatrics and infectious diseases. He was the longest serving chair of the UK Department of Health and Social Care’s Joint Committee on Vaccination and Immunisation (2013-2025), and was a member of WHO’s Strategic Advisory Group of Experts 2016-2022. He is a member of WHOs Product Development Advisory Committee (2025- ). He chaired the Scientific Advisory Group on Vaccines at the European Medicines Agency from 2012-2020. He chaired the UK’s National Institute for Health and Care Excellence (NICE) meningitis guidelines development group (2006-2010), the NICE topic expert group developing quality standards for management of meningitis and meningococcal septicaemia (2011-2013). He was a member of the British Commission on Human Medicines' Clinical Trials, Biologicals and Vaccines expert advisory group since 2013-2024. He was Vice-Master of St Cross College, Oxford, 2017-2021. He was an NIHR senior investigator (2018-2021). He received the “Science Honor and Truth Award” of the Instituto de Patologia en la Altura in La Paz, Bolivia in 2002; the Bill Marshall Award of the European Society for Paediatric Infectious Disease (ESPID) in 2013; the ESPID Distinguished Award for Education and Communication in 2015; the Rosén von Rosenstein medal in 2019 awarded by the Swedish Paediatric Society and the Swedish Society of Medicine; and the Oxford University Vice Chancellor’s Innovation Award in 2020 for his work on typhoid vaccines. He was elected to the Academy of Medical Sciences in 2016 (member of Council 2022-2025) and the Royal Society in 2024 (member of Council 2025-2028). He was awarded honorary membership of the British Society for Immunology in 2021 and Associate membership of the National School of Healthcare Science (2022). He received the James Spence Medal of the Royal College of Paediatrics and Child Health in June 2022 and the 2023 IVI-SK bioscience Park MahnHoon Award. He previously chaired the scientific panel of the Spencer Dayman Meningitis Laboratories Charitable Trust (2002-2006) and was a member of the scientific committee of the Meningitis Research Foundation (2009-2014) and is currently chair of trustees of the Knoop Trust, a Visitor at the Oxford History of Science Museum and a trustee of the Jenner Vaccine Foundation and the Oxford Philharmonic Orchestra Trust. He made the first British ascent of Jaonli (6632m) in 1988 and Chamlang in 1991 (7309m), was the Deputy leader of the successful 1994 British Medical Everest Expedition and climbed Kilimanjaro (5895m) in 2023.
Recent publications
-
Development and validation of the Oxford Benchmark Scale for Rating Vaccine Technologies (OBSRVT), a scale for assessing public attitudes to next-generation vaccine delivery technologies.
Journal article
Kantor J. et al, (2025), Hum Vaccin Immunother, 21
-
Influential drivers of the cost-effectiveness of respiratory syncytial virus vaccination in European older adults: a multi-country analysis
Journal article
Li X. et al, (2025), BMC Medicine, 23
-
Respiratory syncytial virus hospitalisation by chronological month of age and by birth month in infants
Journal article
Guo L. et al, (2025), Nature Communications, 16
-
Risk analysis for outpatient experimental infection as a pathway for affordable RSV vaccine development
Journal article
Siegal EZ. et al, (2025), npj Vaccines, 10
-
Dosing interval is a major factor determining the quality of T cells induced by SARS-CoV-2 mRNA and adenoviral vector vaccines.
Journal article
Murray SM. et al, (2025), Sci Immunol, 10
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006).
Journal article
Li G. et al, (2025), Vaccine, 62
-
Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil
Journal article
Costa Clemens SA. et al, (2025), Mayo Clinic Proceedings Innovations Quality and Outcomes, 9
-
A vaccine emergency – when to overrule parental refusal of vaccination at birth for prevention of vertical transmission of hepatitis B virus?
Journal article
Wilkinson D. and SAVULESCU J., (2025), Archives of Disease in Childhood
-
Salmonella Typhi gut invasion drives hypoxic immune subsets associated with disease outcomes
Journal article
Bossel Ben-Moshe N. et al, (2025), Nature Communications, 16, 6755 - 6755